Discovery opens door for breast, prostate cancer treatments

April 22, 2013
The WAIMR researchers involved in the publication. [Back Row]: Dr Shane Colley, Prof Peter Leedman, Michael Epis, Dr Keith Giles. [Front Row]: Dianne Beveridge, A/Prof Andrew Redfern, Lisa Stuart.

(Medical Xpress)—A team of Western Australian cancer researchers interested in the strong link between hormones and cancer have discovered three new molecules that may have an important role to play in future breast and prostate cancer treatments.

The paper, which has just been published in the leading international journal the Proceedings of the National Academy for Sciences (PNAS), is the result of many years of laboratory work by scientists at the Western Australian Institute for Medical Research (WAIMR) and it is hoped that the discovery will translate to better outcomes for breast and prostate cancer patients in the clinic.

First author on the paper, Perth oncologist Associate Professor Andrew Redfern said that about 200 West Australian cancer patients died each year because of a failure to control oestrogen in female or testosterone in male prostate cancer patients.

"Currently, drugs used to treat these cancers are successful at first, but advanced cancer returns in a proportion of patients," Associate Professor Redfern said.

"Our current treatments are only really targeting part of the signalling pathway related to oestrogen and in 70 percent of cases the tumours are finding a way to sneak around the oestrogen receptor block currently being used. In prostate cancer, the testosterone receptor blocking treatments are also failing and 95% of prostate cancers are testosterone driven. This medical research is looking for new approaches."

Endocrinologist Professor Peter Leedman who leads WAIMR's Laboratory for Hormone Dependent cancers said the team had discovered these molecules while on a "targeted fishing expedition" examining tissue samples from a library, and using a molecule discovered by Texan collaborator Bert O'Malley from Baylor College of Medicine, as "bait."

"These newly identified molecules are key regulators in the oestrogen receptor and the testosterone receptor signalling pathways. In addition to regulating hormone action in these cancers, three of these molecules are part of a complex that processes tiny RNAs inside cells, called microRNAs. In so doing they can regulate a third of all human genes. That's what makes it so interesting, as it would appear that these molecules are great at multi-tasking and can do it from different parts of the cell".

"These molecules are all activating hormone action in these cancer cells, and there is some evidence that too much of one of these molecules in is not good news for cancer patients," he said.

"We hope our paper, which provides big insight into how these molecules work at the bench, will translate towards the bedside and eventually be able to help improve outcomes."

Dr Redfern is using the findings of the PNAS paper in a follow up clinical study to explore the importance of each of the in tissue samples from 500 breast at Royal Perth Hospital.

Explore further: CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

More information: The paper is entitled "RNA-induced silencing complex (RISC) Proteins PACT, TRBP and Dicer are SRA binding nuclear receptor coregulators."

Related Stories

CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

March 6, 2012
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

Lessening the impact of cancer-causing hormones

February 9, 2012
Increasing the production of proteins that help rid the body of toxins may play a crucial role in the fight against breast and prostate cancer, researchers from Flinders University believe.

Researchers confirm breast cancer regulator also found in prostate cancer

June 1, 2012
Researchers at Clarkson University in Potsdam, N.Y., led by Chemistry & Biomolecular Science Professor Costel C. Darie, in collaboration with researchers from Columbia University, have now found the binding partner of TDF, ...

Scientists find new drug target in breast cancer

May 22, 2011
Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.